Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 13, 2011. The report details a corporate action regarding the cancellation of treasury shares authorized by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital adjustments.
Material Changes
- Treasury Share Cancellation: On December 13, 2011, the Company cancelled 30,000,000 Ordinary shares of 25 pence each held as Treasury shares.
- Remaining Treasury Holdings: Following the cancellation, the Company holds 501,157,927 Treasury shares.
- Ownership Percentages: Treasury shares now represent 9.03% of total issued share capital and 9.93% of total voting rights.
- Shares in Issue: The Company has 5,047,261,460 shares in issue (excluding Treasury shares), which represents the total voting rights.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the updated total issued share capital excluding Treasury shares (5,047,261,460).
- Confirm the current percentage of Treasury shares relative to total voting rights (9.93%).
- Check subsequent filings for any further share buybacks or cancellations.